Therapeutic Strategies to Overcome ALK Resistance in Cancer

— —

Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France) Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France)

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France), Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France), Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France) , Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France)

$331.95

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
14 January 2021

Oncology; Respiratory medicine

Series: Cancer Sensitizing Agents for Chemotherapy

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field.

This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment.

Edited by: Luc Friboulet (ERC Principal Investigator and INSERM Team Leader Gustave Roussy Cancer Campu France), Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France), Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France), Luc Friboulet (ERC Principal Investigator and INSERM Team Leader, Gustave Roussy Cancer Campu, France)
Imprint: Academic Press Inc
Country of Publication: United States
Dimensions: Height: 234mm, Width: 191mm,
Weight: 630g
ISBN: 9780128217740
ISBN 10: 012821774X
Series: Cancer Sensitizing Agents for Chemotherapy
Pages: 216
Publication Date: 14 January 2021
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

1. Structure and function of ALK2. ALK rearranged lung cancer: Treatment and outcome3. Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC4. Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, Inflammatory Myofibroblastic Tumor)5. Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy6. Resistance mechanisms to ALK TKI in tumors other than lung cancer7. Therapeutic strategies to overcome ALK resistance in lung cancer8. Novel Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD9. Drug combinations to enhance ALK TKI anti-tumor efficacy in Neuroblastoma10. State of the art and future perspectives

Luc Friboulet, PhD, is ERC Principal Investigator and INSERM team leader at Gustave Roussy cancer campus. He studies the tumor adaptation to kinase inhibitors. Linked to a clinical trial named MATCH-R allowing collection of repeated biopsies in patients treated with ALK, ROS1, RET, EGFR, BRAF, FGFR inhibitors Dr. Friboulet characterizes the resistance mechanisms and establishes new laboratory models.

Reviews for Therapeutic Strategies to Overcome ALK Resistance in Cancer

"""This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment."" --Anticancer Research"

PERHAPS A GIFT VOUCHER FOR MUM?: MOTHER'S DAY

Therapeutic Strategies to Overcome ALK Resistance in Cancer

$331.95

Hardback

Reviews for Therapeutic Strategies to Overcome ALK Resistance in Cancer

See Also

Contact Abbeys

Contact Galaxy

Contact Language

Contact Us

About ABBEY'S